Our study further validated the aberrant activation of STK4 (serine/threonine-protein kinase 4), GSK3α (glycogen synthase kinase 3α), and CDK11B (cyclin-dependent kinase 11B) in liver fibrosis mice and found that their small-molecule inhibitors have antihepatic fibrosis effects. The gene discussed is STK4; the disease is Hepatic fibrosis.